Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
Stephen E. Jones(McKesson (United States)), Rufus Collea(New York Oncology Hematology), Devchand Paul(McKesson (United States)), Scot Sedlacek(McKesson (United States)), Anne Favret(McKesson (United States)), Ira Gore(McKesson (United States)), Deborah Lindquist(Arizona Oncology), Frankie A. Holmes(McKesson (United States)), Mary Ann Allison(McKesson (United States)), Barry Don Brooks(Texas Oncology), Raul M Portillo(Texas Oncology), Svetislava J. Vukelja(McKesson (United States)), Michael S. Steinberg(McKesson (United States)), Christopher Stokoe(Plano Cancer Institute), M Crockett(McKesson (United States)), Yunfei Wang(McKesson (United States)), Lina Asmar(McKesson (United States)), Nicholas J. Robert(Virginia Cancer Specialists), Joyce O’Shaughnessy(McKesson (United States))
Cited by 135
Abstract
Related Papers
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al.|New England Journal of Medicine|2005|5.1k